文献速递乳腺癌

Palbociclib用于高危残留浸润性HR阳性/HER2阴性早期乳腺癌:PENELOPE-B试验

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
PubMed 文献 · J Clin Oncol · 2021-04-01

PURPOSE: About one third of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) will relapse. Thus, additional therapy is needed.…

要点

  • 新辅助化疗后残留高危HR阳性/HER2阴性乳腺癌,加用1年palbociclib未改善iDFS。
  • 最常见相关严重不良事件为感染和血管疾病,发生率9.1%,两组无差异。

核心结论

  • 在新辅助化疗后残留浸润性疾病的HR阳性/HER2阴性早期乳腺癌患者中,内分泌治疗联合1年palbociclib未改善iDFS。

研究设计与样本

  • 患者按1:1随机接受13周期palbociclib 125 mg每日一次(每28天周期第1-21天)或安慰剂,联合内分泌治疗。
  • 主要终点为iDFS,计划在290例iDFS事件后进行最终分析,因两次期中分析采用双侧有效性界值P<.0463。

主要发现

  • 中位年龄49.0岁(范围19-79),多数为ypN+且Ki-67≤15%,59.4%患者临床病理分期-雌激素受体分级评分≥3。
  • 50.1%接受芳香化酶抑制剂,33%绝经前女性在接受他莫昔芬或芳香化酶抑制剂基础上加用黄体生成素释放激素类似物。
  • 亚组间无差异。

关键数值与推荐

  • 最常见相关严重不良事件为感染和血管疾病,发生于113例(9.1%)患者,两组无差异。
  • 报告8例致死性严重不良事件(palbociclib组2例,安慰剂组6例)。

临床怎么用

  • 对于新辅助化疗后残留高复发的HR阳性/HER2阴性早期乳腺癌,不推荐在内分泌治疗基础上常规加用1年palbociclib。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: About one third of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) will relapse. Thus, additional therapy is needed. Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor demonstrating efficacy in the metastatic setting. PATIENTS AND METHODS: PENELOPE-B (NCT01864746) is a double-blind, placebo-controlled, phase III study in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer without a pathological complete response after taxane-containing NACT and at high risk of relapse (clinical pathological staging-estrogen receptor grading score ≥ 3 or 2 and ypN+). Patients were randomly assigned (1:1) to receive 13 cycles of palbociclib 125 mg once daily or placebo on days 1-21 in a 28-day cycle in addition to endocrine therapy (ET). Primary end point is invasive disease-free survival (iDFS). Final analysis was planned after 290 iDFS events with a two-sided efficacy boundary P < .0463 because of two interim analyses. RESULTS: One thousand two hundred fifty patients were randomly assigned. The median age was 49.0 years (range, 19-79), and the majority were ypN+ with Ki-67 ≤ 15%; 59.4% of patients had a clinical pathological staging-estrogen receptor grading score ≥ 3. 50.1% received aromatase inhibitor, and 33% of premenopausal women received a luteinizing hormone releasing hormone analog in addition to either tamoxifen or an aromatase inhibitor. After a median follow-up of 42.8 months (92% complete), 308 events were confirmed. Palbociclib did not improve iDFS versus placebo added to ET-stratified hazard ratio, 0.93 (95% repeated CI, 0.74 to 1.17) and two-sided weighted log-rank test (Cui, Hung, and Wang) P = .525. There was no difference among the subgroups. Most common related serious adverse events were infections and vascular disorders in 113 (9.1%) patients with no difference between the treatment arms. Eight fatal serious adverse events (two palbociclib and six placebo) were reported. CONCLUSION: Palbociclib for 1 year in addition to ET did not improve iDFS in women with residual invasive disease after NACT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Loibl S, Marmé F, Martin M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021. PMID: 33793299. doi:10.1200/JCO.20.03639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。